Structure-activity exploration of a small-molecule allosteric inhibitor of T790M/L858R double mutant EGFR

EGFR is a protein kinase whose aberrant activity is frequently involved in the development of non-small lung cancer (NSCLC) drug resistant forms. The allosteric inhibition of this enzyme is currently one among the most attractive approaches to design and develop anticancer drugs. In a previous study...

وصف كامل

التفاصيل البيبلوغرافية
الحاوية / القاعدة:Journal of Enzyme Inhibition and Medicinal Chemistry
المؤلفون الرئيسيون: Francesca Foschi, Annachiara Tinivella, Valentina Crippa, Luca Pinzi, Luca Mologni, Daniele Passarella, Giulio Rastelli
التنسيق: مقال
اللغة:الإنجليزية
منشور في: Taylor & Francis Group 2023-12-01
الموضوعات:
EGFR inhibitors
allosteric inhibitors
anticancer drugs
drug design
الوصول للمادة أونلاين:https://www.tandfonline.com/doi/10.1080/14756366.2022.2145284

الانترنت

https://www.tandfonline.com/doi/10.1080/14756366.2022.2145284

مواد مشابهة